First Case of *Pseudoclavibacter bifida* Bacteremia in an Immunocompromised Host with Chronic Obstructive Pulmonary Disease (COPD)

Matthijs Oyaert,a Thierry De Baere,b Joke Bryne,c Emmanuel De Laere,d Stan Mariën,e Peter Waets,f Wim Laffuta

Department of Microbiology, Heilig Hart Hospital, Lier, Belgiuma; Institute for Criminalistics and Criminology, Brussels, Belgiumb; Department of Molecular Diagnostics, Heilig Hart Hospital, Roeselare-Menen, Belgiumc; Department of Microbiology, Heilig Hart Hospital, Roeselare-Menen, Belgiumd; Department of Pulmonary Medicine, Heilig Hart Hospital, Lier, Belgiume; Department of Anaesthesiology and Reanimation, Heilig Hart Hospital, Lier, Belgiumf

*Pseudoclavibacter* spp. are Gram-positive, aerobic, catalase-positive, coryneform bacteria belonging to the family of *Microbacteriaceae*. Identification of these species with conventional biochemical assays is difficult. This case report of a *Pseudoclavibacter bifida* bacteremia occurring in an immunocompromised host diagnosed with an acute exacerbation of chronic obstructive pulmonary disease, with a lethal outcome, confirms that this organism may be a human pathogen.

**CASE REPORT**

An 86-year-old male patient suffering from dyspnea, with severe respiratory distress and fever, was admitted to our hospital. In 2006, the patient was diagnosed with class I chronic obstructive pulmonary disease (COPD), for which he was receiving inhaled glucocorticoids and long-acting bronchodilators. COPD exacerbation with a left lobular pneumonia led to hospitalization in July 2011. Treatment with amoxicillin-clavulanic acid was initiated and switched to piperacillin-tazobactam due to respiratory insufficiency. Bronchial aspirates and blood cultures remained negative. Normalization of the lung function parameters and improvement in his general condition led to discharge from the hospital. Other relevant medical history comprised arrhythmia, renal failure, and diabetes mellitus type II.

In September 2011, he presented with dyspnea and fever (body temperature, 38.4°C). No other significant symptoms could be elicited. The patient was hemodynamically stable. Hematological investigations revealed a white blood cell count of 33.4 $\times$ 10³ cells/µl with 96% neutrophils (reference range, 46 to 64%), a hemoglobin level of 10.3 g/dl (reference range, 12.6 to 17.4 g/dl), a hematocrit of 31.0% (reference range, 39.0 to 50.0%), and a platelet count of 245 $\times$ 10³/µl (reference range, 150 $\times$ 10³ to 450 $\times$ 10³/µl). The C-reactive protein level was elevated up to 29.5 mg/dl (normal, <1.0 mg/dl) 3 days after admission (initial value at admission, 20.1 mg/dl), and the serum creatinine level was 3.12 mg/dl (reference range, 0.70 to 1.30 mg/dl). The levels of D-dimers (1,906 ng/ml [reference range, <500 ng/ml]) and digoxin (3.35 µg/liter [reference range, 0.80 to 2.00 µg/liter]) were increased. An arterial blood gas examination revealed decreased pO₂ and pCO₂ levels of 60 mm Hg (reference range, 75 to 100 mm Hg) and 29.1 mm Hg (reference range, 30 to 48 mm Hg), respectively. The bedside gas examination revealed decreased pO₂ and pCO₂ levels of 60 mm Hg (reference range, 75 to 100 mm Hg) and 29.1 mm Hg (reference range, 30 to 48 mm Hg), respectively. A bedside chest X-ray showed infiltrates in the left and right lobes, suggestive of bilateral pneumonia (Fig. 1).

Before intravenous antibiotic treatment with ceftriaxone (2 g every 24 h) was initiated, two aerobic and two anaerobic blood culture bottles (Bactec; Becton, Dickinson, Sparks, MD) were collected at two different fever spikes. One pair was drawn through a catheter; another pair was drawn by peripheral venipuncture. After a mean incubation time of 52.4 h at 35°C, branched, rod-shaped, whitish-grayish, nonfermentative Gram-positive bacteria were observed in both aerobic blood culture bottles. Further bacteriological investigation showed nonmotile, alkaline phosphatase-positive, catalase-positive, and oxidase-negative rods. The isolate grew on blood and chocolate agar after 2 days at 37°C in air supplemented with 5% CO₂. The strain was tested using the commercially available API Coryne test (version 3.0; bioMérieux, Marcy l’Etoile, France), which produced a presumptive identification of *Corynebacterium* spp., with a poor probability (55.7%) of correct identification. For further identification, matrix-assisted laser desorption–ionization time of flight mass spectrometry (MALDI-TOF MS; Microflex, Bruker Daltonik, Bremen, Germany) by the direct-transfer method in combination with the MALDI Biotyper database was used. However, the isolate revealed no clear match with any of the species, with the best identification score being 1,318 for *Arthrobacter castelli*. Due to this poor and unreliable result, phenotypical identification by Phoenix (software version 6.12A/V5/15A; Becton, Dickinson) was performed. Insufficient growth in the control well still resulted in an undetermined identification.

**In vitro** susceptibility testing, performed using Etest (bioMérieux) on Mueller-Hinton II agar with 5% sheep blood (Becton, Dickinson) incubated at 37°C in air supplemented with 5% CO₂ for 24 h, revealed the following MICs: penicillin G, 0.5 mg/liter; cefotaxime, 0.25 mg/liter; ceftriaxone, 0.5 mg/liter; clindamycin 1.5 mg/liter; ciprofloxacin, 0.19 mg/liter; amikacin, 0.25 mg/liter; and vancomycin, 1.0 mg/liter. Despite an initial episode of recovery, the situation deteriorated a few days later. A few hours prior to death, the patient passed an initial episode of recovery, the situation deteriorated a few days later. A few hours prior to death, the patient passed through a fever spike again.

Because of the inconsistent phenotypical identification and the clinical importance of the sample, further identification was per-
formed at the molecular level, DNA was extracted from fresh colonies grown on blood agar (homemade Columbia agar supplemented with 5% horse blood) using the QIAamp DNA minikit (Qiagen, Hilden, Germany) in accordance with the manufacturer’s instructions. The bacterial 16S rRNA gene was amplified using the following primers: 5′-AGA GTT TGA TCG TGG CTC AG-3′ (forward; Escherichia coli positions 8 to 27) and 5′-TAC CTT GTT ACG ACT TCG TCC CA-3′ (reverse; E. coli positions 1504 to 1485) (1, 2). Amplification products of approximately 1,350 nucleotides (nt) were checked by agarose gel electrophoresis (2%).

FIG 1 X-ray radiograph of the patient on the day of admission showing alveolar infiltrates in the right upper lobe and lower lobe and in the left middle lobe.

GeneBase software (Applied Maths, Sint-Martens-Latem, Belgium) and was based on the neighbor-joining method.

This case report describes, to our knowledge, the first *Pseudoclavibacter bifida* septicemia in an immunocompromised COPD patient with bilateral pneumonia. These coryneform bacteria are widely distributed in the environment, especially in soil (3). To date, identification to the species level requires special analysis (i.e., 16S rRNA gene sequencing), because phenotypic characteristics are not sufficiently reliable for identification of this microorganism (Table 1).

For the first time, Lin et al. described the genus *Zimmermannella* (family of Microbacteriaceae in the class Actinobacteria), with *Z. helvolu* as the type species and three novel species, *Z. alba*, *Z. bifida*, and *Z. faecalis*, in 2004 (3). However, the genus *Pseudoclavibacter* was first described by Manaia et al., who reclassified *Brevibacterium helvolus* as the type strain of the species, renaming it *Pseudoclavibacter helvolus*. According to the previously published name by Manaia et al., *Z. helvolus* should be named *Pseudoclavibacter helvolus* and the three species *Z. alba*, *Z. bifida*, and *Z. faecalis* should be renamed *P. alba*, *P. bifida*, and *P. faecalis* (7). In fact, *Z. helvolus* is an earlier homotypic synonym of *P. helvolus*, and the genus name *Zimmermannella* is therefore considered to be illegitimate. Based on nomenclature rules, the name *Pseudoclavibacter* has priority. Until now, no publication of the official conversion of the three other species has appeared. The genus *Pseudoclavibacter* already consists of four official species (*P. caeni*, *P. chungangensis*, *P. helvolus*, and *P. soli*), all isolated out of soil material (5–8).

Since 2004, only one case report has described the potential clinical importance of a *Pseudoclavibacter*-like organism as a cause of cutaneous and subcutaneous infection in a human (9). This isolate (FJ375951) is included in the phylogenetic tree and appears to be closely related to our *P. bifida* strain (Fig. 2). This, together with clinical data published by Lemaitre et al., suggests that the group of *P. bifida* strains might be of clinical importance (9). The original isolates of *P. bifida* and *P. alba* were also human isolates (human wounds, urine, and blood). In our case, *P. bifida* was isolated from blood in an immunocompromised COPD patient who was admitted to the hospital due to acute respiratory distress syndrome with dyspnea. Eight days later, the patient died due to bilateral pneumonia.

Laboratory identification of the organism is challenging and impossible using routine laboratory protocols or using the API Coryne test. Fermentation of rhamnose and the presence of β-glucosidase are variably determined (Table 1) (3, 5, 6, 8). *P. bifida* forms typically whitish-to-yellowish colonies on blood agar and are catalase and alkaline phosphatase positive; oxidase is negative. Optimal growth occurs at 30°C (3).

The use of the Gram-positive identification panel on a Phoenix automated system (Becton, Dickinson) yielded no identification due to insufficient growth in the control well. However, the species is not included in the Epicenter Database. Based on the available test results, a presumptive identification of *Corynebacterium* spp. was made, although glucose fermentation was not observed. The final identification of *P. bifida* required analysis by molecular genetic methods relying on PCR, direct DNA sequencing, and GenBank research. An explanation for the rarity of diseases caused by *Pseudoclavibacter* species is the relatively low pathogenicity of this genus and, more generally, of coryneform bacteria. On the
other hand, identification of these bacteria to the species level remains a challenge for most microbiology laboratories, which may explain the low rate of recovery of these strains.

Identifying coryneform bacteria may help physicians distinguishing between infection and colonization. Some coryneform bacteria are known as opportunistic pathogens in (immunocompromised) patients (e.g., *Corynebacterium jeikum*); others are thought to be “innocent bystanders.” By identifying coryneform bacteria to the species level, a physician can conclude that a specific species may be the cause of infection.

*P. bifida* infections should be treated according to the antibiogram. We performed susceptibility testing by Etest and found high MICs of clindamycin, confirming the results of Lemaitre at al (9). MICs of other antibiotics tested confirm the results of Mages et al., who have tested the largest cohort of clinically important *Arthrobacter*-like bacteria so far (10). For ceftriaxone, we found a
MIC of 0.5 mg/liter, to which coryneform bacteria are still susceptible according to the CLSI M45-A2 document (11). Although P. bifida is not included in this list, on the basis of this CLSI document, we formulate advice for an antibiotic. Despite optimal antibiotic treatment, the patient’s situation deteriorated a few days later. A few hours prior to death, the patient passed through a fever spike again.

In conclusion, the identification of P. bifida as a cause of bacteremia in an immunocompromised host with COPD was possible only with the application of modern techniques of molecular diagnosis, like 16S rRNA gene sequencing. Attempts to identify the microorganism by standard biochemical characterization tests routinely performed in diagnostic laboratories produced misleading results, with a classification of Corynebacterium spp. This case emphasizes Pseudocloibacter species as a potential pathogen in immunocompromised patients.

**Nucleotide sequence accession number.** The GenBank accession number for the partial 16S rRNA gene sequence of P. bifida MR128036 is KC757349.

**ACKNOWLEDGMENTS**

We are grateful to G. Coppens, H. De Beenhouwer, and J. Frans, who performed conformational and supplementary identification tests.

We declare that we have no conflicts of interest.

**REFERENCES**


